Laboratory diagnosis of Ebola virus disease and corresponding biosafety considerations in the China Ebola Treatment Center
- PMID: 26952811
- DOI: 10.3109/10408363.2016.1160866
Laboratory diagnosis of Ebola virus disease and corresponding biosafety considerations in the China Ebola Treatment Center
Abstract
Ebola virus disease (EVD), caused by Ebola virus (EBOV), is a potent acute infectious disease with a high case-fatality rate. Etiological and serological EBOV detection methods, including techniques that involve the detection of the viral genome, virus-specific antigens and anti-virus antibodies, are standard laboratory diagnostic tests that facilitate confirmation or exclusion of EBOV infection. In addition, routine blood tests, liver and kidney function tests, electrolytes and coagulation tests and other diagnostic examinations are important for the clinical diagnosis and treatment of EVD. Because of the viral load in body fluids and secretions from EVD patients, all body fluids are highly contagious. As a result, biosafety control measures during the collection, transport and testing of clinical specimens obtained from individuals scheduled to undergo EBOV infection testing (including suspected, probable and confirmed cases) are crucial. This report has been generated following extensive work experience in the China Ebola Treatment Center (ETC) in Liberia and incorporates important information pertaining to relevant diagnostic standards, clinical significance, operational procedures, safety controls and other issues related to laboratory testing of EVD. Relevant opinions and suggestions are presented in this report to provide contextual awareness associated with the development of standards and/or guidelines related to EVD laboratory testing.
Keywords: Ebola virus; Ebola virus disease; Zaire Ebola virus; biosafety control measures; laboratory diagnosis.
Similar articles
-
Rapid deployment of a mobile biosafety level-3 laboratory in Sierra Leone during the 2014 Ebola virus epidemic.PLoS Negl Trop Dis. 2017 May 15;11(5):e0005622. doi: 10.1371/journal.pntd.0005622. eCollection 2017 May. PLoS Negl Trop Dis. 2017. PMID: 28505171 Free PMC article.
-
Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients.Clin Chem Lab Med. 2015 Nov;53(12):1967-73. doi: 10.1515/cclm-2015-0119. Clin Chem Lab Med. 2015. PMID: 26053010
-
Ebola virus disease: Biological and diagnostic evolution from 2014 to 2017.Med Mal Infect. 2018 Mar;48(2):83-94. doi: 10.1016/j.medmal.2017.11.002. Epub 2017 Dec 8. Med Mal Infect. 2018. PMID: 29224715 Review.
-
Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease.J Infect Dis. 2018 Jul 13;218(4):555-562. doi: 10.1093/infdis/jiy199. J Infect Dis. 2018. PMID: 29659889 Free PMC article. Clinical Trial.
-
Towards detection and diagnosis of Ebola virus disease at point-of-care.Biosens Bioelectron. 2016 Jan 15;75:254-72. doi: 10.1016/j.bios.2015.08.040. Epub 2015 Aug 20. Biosens Bioelectron. 2016. PMID: 26319169 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials